Does Tazocin (piperacillin/tazobactam) cover Methicillin-resistant Staphylococcus aureus (MRSA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

Aerobic bacteria Gram-positive bacteria Staphylococcus aureus (methicillin susceptible isolates only)

The FDA drug label does not answer the question about MRSA coverage, as it specifically mentions methicillin susceptible isolates only for Staphylococcus aureus, implying it may not be effective against methicillin-resistant Staphylococcus aureus (MRSA) 1.

From the Research

No, Tazocin (piperacillin-tazobactam) does not effectively cover MRSA (Methicillin-resistant Staphylococcus aureus). Tazocin is a combination antibiotic containing piperacillin, a penicillin-class antibiotic, and tazobactam, a beta-lactamase inhibitor. MRSA has developed resistance to all beta-lactam antibiotics, including penicillins, cephalosporins, and carbapenems, through the production of an altered penicillin-binding protein (PBP2a) that has low affinity for beta-lactam antibiotics.

For MRSA infections, appropriate antibiotics include vancomycin, linezolid, daptomycin, ceftaroline, or trimethoprim-sulfamethoxazole, depending on the site and severity of infection. According to a recent study 2, linezolid may be a preferred antibiotic for the treatment of MRSA-caused infections, showing superiority in clinical and microbiological success without difference regarding safety.

When treating suspected or confirmed MRSA infections, it's essential to use antibiotics specifically active against MRSA rather than relying on Tazocin, which remains effective against many other bacteria including Pseudomonas aeruginosa and various gram-negative organisms. The most recent and highest quality study 2 supports the use of linezolid as a potential first-line drug against MRSA bacteremia, with comparable effectiveness and safety to vancomycin and daptomycin.

Key points to consider:

  • Tazocin does not cover MRSA due to its resistance to beta-lactam antibiotics
  • Appropriate antibiotics for MRSA infections include vancomycin, linezolid, daptomycin, ceftaroline, or trimethoprim-sulfamethoxazole
  • Linezolid may be a preferred antibiotic for MRSA-caused infections, according to recent studies 2
  • It's essential to use antibiotics specifically active against MRSA when treating suspected or confirmed MRSA infections.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.